Gastroesophageal Reflux Disease (GERD) Market 2025-2029: Unveiling Growth Developments with the Latest Updates
Focused on real-world business use, this report highlights what’s changing in the gastroesophageal reflux disease (gerd) market and what companies should prepare for next.
Gastroesophageal Reflux Disease (GERD) Market Valuation Forecast: What Will The Market Be Worth By 2025?
The gastroesophageal reflux disease (gerd) market size has grown marginally in recent years. It will grow from $5.25 billion in 2024 to $5.33 billion in 2025 at a compound annual growth rate (CAGR) of 1.6%. The growth in the historic period can be attributed to lifestyle and dietary changes, obesity epidemic, growing awareness about gerd treatment, globalization of pharmaceutical industry, investments for gerd treatments.
The gastroesophageal reflux disease (gerd) market size is expected to see steady growth in the next few years. It will grow to $5.95 billion in 2029 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, emergence of biomarker, growing number of screening programs for gerd, increasing prevalence of heartburn, increased demand for medical equipment. Major trends in the forecast period include diagnostic advancements, surgical advancements, development of targeted therapies, adoption of telehealth services.
Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12917&type=smp
What Are The Key Factors Driving Growth In The Gastroesophageal Reflux Disease (GERD) Market?
The growing prevalence of esophageal diseases is expected to propel the growth of the gastroesophageal reflux disease (GERD) market going forward. Esophageal diseases are medical conditions that affect the esophagus, a muscular tube connecting the mouth to the stomach. The treatment of esophageal diseases aims to alleviate symptoms, improve quality of life and prevent complications, ultimately promoting better overall health and well-being for gastroesophageal reflux disease-affected individuals. For instance, in January 2023, according to the American Cancer Society, a US-based Professional organization, about 21,560 new esophageal cancer cases are diagnosed yearly in the United States, with 16,120 deaths from esophageal cancer. Therefore, the growing prevalence of esophageal diseases drives the growth of the gastroesophageal reflux disease (GERD) market.
Emerging And High-Growth Segments In The Global Gastroesophageal Reflux Disease (GERD) Market
The gastroesophageal reflux disease (gerd)market covered in this report is segmented —
1) By Drug Type: Antacids; Proton Pump Inhibitors; H2 Receptor Blocker; Pro Kinetic Agents; Dopamine Receptor Antagonist; EndoCinch; Stretta; EsophyX; Transoral Incisionless Fundoplication (TIF)
2) By Procedure: Invasive; Minimally Invasive
3) By End-Users: Hospital; Homecare; Specialty Clinics
Subsegments:
1) By Antacids: Calcium Carbonate; Magnesium Hydroxide; Aluminum Hydroxide
2) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
3) By H2 Receptor Blockers: Ranitidine; Famotidine; Nizatidine; Cimetidine
4) By Prokinetic Agents: Metoclopramide; Domperidone
5) By Dopamine Receptor Antagonists: Prochlorperazine; Droperidol
6) By EndoCinch: Endoscopic Suturing Systems
7) By Stretta: Radiofrequency Ablation Systems
8) By EsophyX: Transoral Fundoplication Systems
9) By Transoral Incisionless Fundoplication (TIF): TIF Devices And Systems
Gastroesophageal Reflux Disease (GERD) Market Future Trends
Major companies operating in the gastroesophageal reflux disease (GERD) market are focusing on introducing innovative gastroesophageal reflux disease treatment devices to sustain their position in the market. For instance, in April 2023, Laborie Medical Technologies, a US-based medical technology company, launched the new alpHaONE wireless pH-capsule reflux testing diagnostic system designed for diagnosing gastroesophageal reflux disease (GERD). The system provides up to 96 hours of monitoring data and offers a compact design with enlarged buttons and a fail-safe capsule delivery system. The system features a software application with a virtual instruction program and user-customizable symptom buttons for improved user experience.
Key Gastroesophageal Reflux Disease (GERD) Company Insights:
Major companies operating in the gastroesophageal reflux disease (GERD) market are GlaxoSmithKline PLC, SRS Life Sciences, Johnson & Johnson Services Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Reckitt Benckiser Group PLC, Eisai Co. Ltd., Pfizer Inc., Medtronic PLC, Teva Pharmaceuticals, HK inno.N Corporation, Sebela Pharmaceuticals, Mylan N.V., Bausch Health Companies Inc., Johnson & Johnson MedTech, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Salix Pharmaceuticals Inc., Almirall S.A., HK inno.N Corporation, SRS Life Sciences Pte. Ltd.
View the full gastroesophageal reflux disease (gerd) market report here:
https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-gerd-global-market-report
How Does Gastroesophageal Reflux Disease (GERD) Market Growth Vary Across Major Regions?
North America was the largest region in the gastroesophageal reflux disease (GERD) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastroesophageal reflux disease (GERD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Americas +1 310–496–7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment